What Growth Marketing Actually Means for a Pre-Revenue Biotech

Open any guide to growth marketing and you will find the same vocabulary. Customer acquisition cost. Monthly recurring revenue. Pipeline velocity. Conversion rate. Payback period. Now apply that to a biotech with a lead asset in preclinical development and a first-in-human study two years out. You have no customers. No revenue. No pipeline in the sales sense of the word. Every metric in the standard playbook is either zero or meaningless, and the standard playbook has nothing to say to you.

So founders do one of two things. They ignore marketing entirely, on the theory that the science will speak for itself, or they hire someone who runs the software playbook anyway and burns budget optimizing a funnel that has nothing at the end of it.

Both are mistakes, and they come from the same root error: nobody stopped to ask what growth actually means for a company whose product is a decade from market.

This piece: ‘Growth Marketing for a Pre-Revenue Biotech’ answers that question first, then works through everything that follows from it.

• What growth actually is when there is no revenue.
• Who the four audiences are and why they overlap.
• The five channels that genuinely move the needle.
• How to reach named investor and partner targets.
• The metrics that connect marketing to fundraising outcomes.
• A 12-month roadmap for building the system.

And finally the resourcing question, because most founders get the “what” roughly right and then staff it in a way that guarantees it fails.

First, Redefine Growth

Everything downstream depends on getting this right.

You Have No Customers, So Growth Is Not Customer Acquisition

The premise of conventional growth marketing is that there is something to sell and someone to sell it to. Remove both and the entire discipline needs rebuilding from the foundation. This is not a matter of adjusting the metrics. It is a different job.

The mistake to avoid is assuming your marketing will look like a software company’s marketing with a longer sales cycle. It will not. The audience is different, the currency is different, and the thing you are trying to grow is different.

What Growth Actually Means Before Revenue

For a pre-revenue biotech, growth is the compounding of four things.

Capital. Getting funded, at better terms, faster, and by better investors, whether that capital is equity or non-dilutive funding through SBIR, STTR, and grant programs.

Partnerships. Pharma, CDMO, academic, and clinical relationships that accelerate development or validate the science.

Talent. Attracting the scientific and operational people who will not join an invisible company.

Credibility. The reputation that makes all three of the above easier, and which compounds over years.

Notice that all four are relationship and reputation outcomes, not transaction outcomes. That is the defining feature of growth in this sector, and it explains why the standard playbook fails so completely.

The economics reinforce the point. A biotech’s value is built almost entirely in the years before it sells anything. The data, the partnerships, the capital, and the credibility that make the company worth something all accrue pre-revenue, and the commercial payoff, if it arrives, arrives later and is far from certain.

McKinsey’s analysis of first-time biotech launchers found that self-launching companies are consistently less successful than experienced ones, and separate McKinsey work on launch performance found that the median first-time launcher reaches only about 63 percent of analysts’ expectations, against 93 percent for experienced launchers, with fewer than half of biotech launches hitting forecast at all. Scientific promise does not translate automatically into value. The pre-revenue period is where the value is actually made or lost.

The Currency Is Trust in the Science

Your audience is an ecosystem, not a buyer persona. Investors, pharma business-development teams, CDMOs, key opinion leaders, regulators by reputation, and future hires all evaluate you, and they all evaluate you on the same thing: the credibility of your science and your team.

That has a direct consequence for how you communicate. When commercialization is years away, the job of marketing is to build the scientific credibility and reputation that attract partners, investors, and talent. The audience is the ecosystem, and the currency is trust in the science rather than a filled-in form.

This is not a soft claim. In the broader B2B world, research from Edelman and LinkedIn has found that roughly three-quarters of decision-makers consider an organization’s substantive thought-leadership content a more trustworthy basis for judging its capabilities than its marketing materials, and that nine in ten are more receptive to outreach from companies that consistently publish high-quality thinking.

In biotech, where the audience is more rigorous and more risk-averse than almost any other, that dynamic is amplified. Promotional marketing does not just underperform here. It actively erodes the trust you need, because a scientific audience reads hype as a signal of weakness.

So the job is not demand generation. It is credibility generation. Everything else follows.

I have seen this play out directly with a pre-revenue diagnostics founder I worked with. He published one mechanism explainer on the platform’s approach to an underserved biomarker category, written for a scientifically literate but non-specialist reader.

Weeks later, an institutional investor who had been quietly tracking the space referenced that exact article on the first call, before any formal outreach had happened on either side. The content had already done the work of building conviction. That is what credibility generation looks like in practice, and it is the outcome every channel in this piece is built to produce.

The Four Audiences a Pre-Revenue Biotech Markets to at Once

One of the most operationally demanding features of pre-revenue biotech marketing is that you do not get to address one audience at a time. Every public communication, every conference appearance, every published article is evaluated simultaneously by four distinct audiences whose questions differ but whose underlying test is the same.

Audience 1: Investors

Institutional and angel investors assess scientific credibility, milestone progress, team quality, and commercial awareness through every public touchpoint you generate, long before a formal raise begins. Investors research founders online before agreeing to a first meeting, and the investor is not merely a recipient of pitch decks and cold emails.

They are a continuous observer of every signal you send into the public domain, and their pre-meeting conviction is shaped by the accumulated weight of those signals before the first conversation.

This is why content matters more than founders expect. Thought leadership does not just build awareness; it changes buying behavior. Edelman and LinkedIn found that 75 percent of decision-makers said a piece of thought leadership prompted them to research a product or service they had not previously considered, and that 70 percent of C-suite leaders said thought leadership had led them to reconsider an existing vendor. Translated into biotech: what an investor reads about you before you meet is often what decides whether the meeting happens.

Audience 2: Pharma and Strategic Partners

Pharma and CDMO partners are evaluating whether your platform or asset fits their pipeline and whether you are a credible, operationally rigorous company to work with. They extend their own regulatory accountability to anyone they partner with, which makes their diligence on a potential partner at least as demanding as their diligence on an acquisition.

Your published data, scientific communications, and conference presence are the primary evidence base for that evaluation in the early stages of any discussion.

Audience 3: Scientific Talent

Senior scientists and operational leaders weighing an offer from an early-stage biotech will research the founding team’s scientific credibility, the quality of the published work, the composition of the advisory board, and the company’s visible engagement with the field before accepting a role whose security depends on the company raising its next round.

An invisible company cannot recruit the people who would make it fundable. Visibility is a hiring input, not a vanity project.

Audience 4: Scientific Peers, Collaborators, and KOLs

The engagement of recognized scientific opinion leaders signals legitimacy to all three of the audiences above at once. An investor who sees three respected KOLs in a disease area on your scientific advisory board is receiving a different credibility signal than one who sees a sparse board with no recognizable names.

The scientific community’s visible engagement with your company is itself a marketing output, and cultivating those relationships is a marketing function even when it does not feel like one.

The unifying principle is simple, and it is the reason the whole system holds together: all four audiences judge you on the credibility of your science and team, so credibility-led work serves all four simultaneously. You are not running four campaigns. You are building one reputation that four audiences read differently.

The Signal Loop: One Message, Four Readings

Here is the mental shift that follows from having four audiences. Every visible communication enters a multi-audience evaluation at the same time.

Publish one strong clinical update on a Monday and you will spend the rest of the week answering four different questions about it. Scientists ask whether the methodology holds up. Investors ask whether the result changes the value of the program. Potential partners ask whether the asset fits their pipeline.

Candidates ask whether the company is building something real enough to join. One message, four evaluations, one chance to calibrate it correctly.

Awareness alone has limited value in this environment. A company can get attention and still fail if the audience cannot quickly place the science, judge the maturity of the program, and see the business case. The answer is not to write four separate messages for four audiences.

The answer is a single layered communication where the scientific precision satisfies the scientists, the milestone framing satisfies the investors, the platform differentiation satisfies the partners, and the team visibility satisfies the talent, all inside the same document, the same post, or the same abstract.

The most common failure point in early-stage biotech is a disconnect between these layers. The research team talks in mechanisms and endpoints. The founder talks in mission. The deck talks in milestones. The careers page talks in culture. None of those stories is wrong. They are just disconnected, and a sophisticated reader notices the seams. The work of the signal loop is connecting them into one coherent narrative that serves every audience, every time.

What Growth Marketing Actually Consists Of

If growth means capital, partners, talent, and credibility, then the work is specific, and it is not what most people picture when they hear “marketing.”

Positioning the science as an investment and partnership case. Translate the mechanism into a story an investor or a business-development executive can evaluate, without dumbing it down for a scientific reader. This is capital raise marketing in its most literal sense: define what you are, a platform generating many programs, or an asset company built around a lead. Those are valued differently and pitched differently, and blurring them costs you.

Get the competitive landscape right, because sophisticated audiences will place you against the other approaches in development whether you frame it or not.

Investor-facing visibility. Investors research you before they take a meeting. What they find is either a track record of thinking built before the fundraise or a blank. This is the highest-leverage marketing a pre-raise company does.

Founder and KOL authority. In a credibility economy, the founder’s public expertise is a company asset. Scientific thought leadership from your scientific leaders outperforms brand-led promotion. KOL relationships lend independent validation, and independent validation is what a risk-averse audience is actually looking for.

Partner and business-development pipeline. Business development is not something that starts after the science is finished. It is a parallel track. The most successful founders build a pipeline of opportunities rather than waiting for investors and partners to knock. Account-based approaches fit well here, because your targets are a named, finite list, not a broad market.

Conference and content systems. Biotech runs on conferences. The system is what turns a panel appearance into an ongoing relationship rather than a one-off conversation. The webinar funnel, the publication strategy, and the content engine are the machinery that keeps credibility compounding between milestones.

Compliant execution. Everything above has to work within intellectual property, regulatory, and disclosure constraints. This is not a footnote. It is a core design requirement, and it is where generalist marketers get companies into trouble.

The 5 Growth Marketing Channels That Actually Work for Pre-Revenue Biotech

Five channels consistently deliver meaningful growth outcomes for pre-revenue biotech founders. All five are credibility-first rather than volume-first. The execution below is where the strategic layer above becomes tactical.

Channel 1: Scientific Thought Leadership and Content

Scientific thought leadership is the highest-credibility content available to a pre-revenue biotech, because it carries the implicit endorsement of rigor rather than polish.

Peer-reviewed pre-prints, mechanism explainers, clinical data visualizations, and educational articles written to a sophisticated non-specialist level are the formats that move investor and partner audiences, because they demonstrate exactly what those audiences are evaluating: the quality and specificity of the team’s scientific thinking. Founder-led content built from your scientific leaders’ own thinking builds trust where brand-led promotion erodes it.

Calibration is the whole game. Content written for a pure peer-science reader, assuming everyone has a PhD in the relevant field, closes off the investors and partners who need the science explained in precise but accessible language. Content written for a scientifically literate non-specialist serves both audiences better than content optimized for either one alone.

A company that consistently publishes substantive work on a topic central to its thesis becomes the reference point for anyone researching that space, which is an outcome no advertising can buy.

Channel 2: LinkedIn and Founder-Led Visibility

LinkedIn is the primary surface on which all four audiences evaluate biotech founders before any formal conversation. It is not a branding channel. It is an investor-facing research channel that happens to double as a distribution platform, and both functions run at once.

The founder’s personal profile is the highest-reach, highest-trust LinkedIn asset a pre-revenue biotech has, and most founders treat it as an afterthought behind the company page. That is backwards, and it is the core argument behind a deliberate LinkedIn strategy for biotech CEOs preparing to raise capital.

Individual profiles consistently outperform company pages on organic reach and engagement: independent measurement, including Sprout Social’s 2026 Index across tens of millions of posts, puts median engagement on personal profiles several times higher than on company pages, and the mechanism is well understood, since peers engage with people far more readily than with brand accounts.

The credibility gap runs the same direction. Content from an identifiable individual is read as more trustworthy than the same message from a logo.

The compounding effect matters more than any single post. A founder who publishes substantive scientific and commercial commentary consistently across a year builds a public record of thinking that investors encounter during pre-meeting research, that partners reference when judging strategic awareness, and that strong scientists read when deciding whether the team is worth following.

Channel 3: Earned Media and Trade Press

Earned coverage from outlets like STAT News, Endpoints News, MedTech Dive, BioPharma Dive, and Fierce Biotech provides third-party editorial validation that self-published content cannot replicate.

When an investor meets your company for the first time through an independent article rather than your own blog, the credibility signal is categorically different: an editorial organization with domain expertise looked at your work and judged it worth covering.

The relationship-building that precedes earned media is itself the work. Introducing your founding team to relevant journalists as expert sources on their therapeutic area, rather than as subjects seeking coverage, is a sustained marketing function, not a one-time press release. The most efficient path to a first citation is to be useful to a reporter months before you need anything from them.

Channel 4: Conference and Peer Presence

Conferences create the live scrutiny and relationship access that no digital channel replicates. For a pre-revenue biotech, the right conference is one where all four target audiences are present at once: investors evaluating new programs, pharma business-development teams assessing partnerships, scientific peers who can validate the approach, and potential hires watching which companies attract serious discussion.

The distinction between speaking and attending matters enormously. A speaker slot signals that an independent programming committee, which receives far more applications than it accepts, judged your perspective worth a room of investors and scientists. An attendee badge signals that you bought a ticket.

The credibility gap between those two outcomes is large, and it is worth the effort of a speaking application submitted six to nine months ahead.

Channel 5: SEO, GEO, and Digital Infrastructure

Your website is the first surface an investor or partner reaches when they search your name or company after any other contact point, whether a conference introduction, a cold email, or a LinkedIn post. What they find there is a direct input into whether the meeting happens at all. A vague site with unclear pipeline information does not create a neutral impression. It creates a negative one.

SEO, optimizing content to surface in search for your therapeutic area and technology, builds discoverability that brings investors and partners to you through search rather than requiring you to reach them first. GEO, generative engine optimization, extends this by structuring content for citation by AI answer engines like Perplexity and ChatGPT, which investors and partners increasingly use as research tools when evaluating unfamiliar companies and disease areas.

This is the searchable authority layer: the technical quality of the infrastructure, load speed, mobile responsiveness, structured data, and clear organization, is as much a credibility signal as the content it carries. If your site crawls on mobile, you have lost a scientifically curious investor before the conversation starts.

Account-Based Marketing for Biotech: Reaching Named Investor and Partner Targets

Account-based marketing is the concept from the B2B world that translates most cleanly into pre-revenue biotech. Rather than broadcasting to a broad anonymous audience and optimizing for aggregate metrics, ABM focuses on a defined set of named accounts with specific, relevant content designed to move each relationship along a path.

In this context, the named accounts are the 30 to 50 target investors and 10 to 20 strategic partner targets you have identified and tiered through your investor pipeline system. Four tactics do most of the work.

Content alignment. Publish work that directly addresses the scientific or commercial questions specific named investors or partners have raised publicly, through their own writing, conference comments, or posts. An investor who has written about the limitations of current approaches in a disease area will notice a company whose next article addresses those limitations from a new angle.

LinkedIn engagement. Comment substantively on the posts of named targets, adding data points, a contrarian read, or a well-reasoned question, before any direct outreach. This builds low-stakes familiarity that pre-warms the eventual cold email or introduction.

Investor updates with targeted references. Send quarterly updates that include a specific piece of content or milestone calibrated to the recipient’s stated thesis, rather than an identical progress note blasted to every contact.

Conference scheduling. Use the structured one-on-one meeting systems at events like BIO International and LSX to pre-schedule time with named accounts from your target list, rather than relying on chance encounters on the show floor.

The Metrics That Actually Matter for Pre-Revenue Biotech Marketing

Because customer acquisition cost and recurring revenue do not apply, you need a different scoreboard. This is where most engagements go wrong, since a marketer measured on the wrong things will optimize for the wrong things. Followers, page views, and email subscribers are measurement instruments at best. They are not outcomes.

What to Measure Instead

Track the leading indicators of the four growth outcomes.

Capital. Inbound investor interest, the warmth and quality of first meetings, how often an investor arrives already knowing who you are, the proportion of first meetings preceded by content engagement, and time-to-close on a round.

Partnerships. Conversations opened with named pharma and CDMO targets, and progression through business-development stages.

Talent. Inbound candidate quality, and whether senior scientific hires cite your visibility as a reason they engaged.

Credibility. Speaking invitations, KOL and advisory-board relationships initiated, trade-press mentions and external citations, and whether your name surfaces in conversations you were not part of.

Be Skeptical of Borrowed Benchmarks

You will see marketing providers cite revenue-growth statistics from cross-industry studies. Treat them with suspicion. They come from companies that have revenue, which you do not, and they tell you nothing about whether an approach will produce capital, partnerships, or credibility for a preclinical therapeutics company. Ask instead for evidence from life-science engagements, and ask what changed for those companies in the four terms above.

Connect Everything to the CRM

The failure mode is metrics that live in a separate analytics dashboard, disconnected from the pipeline. Every measure above should feed a single system where investor pipeline warmth is visible alongside content engagement, so that a named investor’s interaction with a founder post, a webinar attendance, or a website visit updates that investor’s status in the pipeline directly. Marketing that does not connect to the pipeline is marketing you cannot evaluate.

Common Growth Marketing Mistakes in Pre-Revenue Biotech

Treating marketing as a layer applied after the science is done. The investor, partner, and talent audiences that determine whether the company survives are forming impressions continuously, from the earliest stages of your public existence. Starting marketing six weeks before a formal raise is starting twelve months too late.

Using promotional language instead of scientific communication. Phrases like “revolutionary platform,” “transformative therapy,” and “breakthrough approach” are the vocabulary of advertising, not science, and they trigger skepticism in an audience trained to evaluate evidence. Every public claim should be supportable with specific data.

Prioritizing the company page over the founder’s profile. A company page with 500 followers generates a fraction of the reach and trust of a founder’s personal profile with 2,000 followers who publishes substantive content consistently. Treating the personal profile as less important than the page is one of the most common and most costly channel-allocation errors in early-stage biotech.

Attending conferences rather than speaking at them. Attendance generates access. Speaking generates credibility. A programming committee’s decision to give you a slot is a form of peer validation that attendance alone cannot produce.

Publishing content calibrated for pure peer-science audiences. Content that requires a PhD in the specific disease area to follow closes off the investors and partners who are your primary growth audience. The calibration target is the scientifically literate non-specialist, not the peer reviewer.

Neglecting the website as a credibility checkpoint. A static or outdated site does not read as neutral to the investors and partners who will visit it before agreeing to meet. It reads as unreadiness.

A Practical 12-Month Growth Marketing Roadmap for Pre-Revenue Biotech

Q1: Foundation (Months 1 to 3)

The first quarter builds the communication architecture before you deploy anything through it.

• Define the company’s core scientific and commercial narrative. Write a 300-word document that tells the same story for all four audiences: the clinical problem, the scientific hypothesis, the differentiation argument, the team’s specific qualifications, and the milestone this stage will fund. Anchor every later communication to it, including the eventual investor pitch deck.
• Audit and rebuild the website to investor-grade standards. At minimum: a plain-language description of the science and the unmet need, a pipeline overview with current stage indicated, a team page with specific credentials and publications, an investor section with contact information, and a content hub with at least two substantive articles. Make it fast, mobile-optimized, and properly structured for AI indexing.
• Optimize the founder’s LinkedIn profile. Rewrite the headline to communicate scientific thesis and stage, not just title. Rewrite the About section as a founder narrative. Feature the best existing content.
• Identify and qualify the 30 to 50 named investor targets and 10 to 20 named partner targets that make up the ABM audience.
• Set up the CRM with content-engagement tracking, so pipeline warmth and content engagement live in one place from day one.

Q2: Content and Visibility Launch (Months 4 to 6)

The second quarter produces your first public assets and starts warming the pipeline.

• Publish the first long-form thought-leadership piece, 700 to 1,000 words on a topic central to the thesis, calibrated for a scientifically literate non-specialist. Aim for placement in a relevant trade outlet; if that is not yet achievable, publish on the company blog with proper SEO and GEO structure.
• Begin consistent LinkedIn posting: two substantive posts per week from the founder’s personal profile, rotating through scientific-thesis posts, founder-journey reflections, market commentary, milestone updates framed around meaning, and team spotlights.
• Submit one conference speaking application to the most relevant venue for your stage and area, planning for a Q3 appearance.
• Introduce yourself to three to five trade journalists with a brief, personalized note offering expertise as a source, not pitching the company.
• Begin substantive LinkedIn engagement with named investor and partner targets, two to three comments per week.

Q3: Amplification (Months 7 to 9)

The third quarter converts the foundation into third-party validation and deepens the pipeline.

• Attend and, if accepted, speak at the target conference. Run the three-post sequence: a pre-event post on what you are looking forward to, a during-event post on a key insight, and a post-event synthesis. Use the partnering system to pre-schedule five to ten meetings with named targets.
• Pursue the first earned-media placement by following up with the journalists you met in Q2. Pitch a trend in the therapeutic area rather than the company, and aim for a source citation rather than a profile.
• Build and publish GEO-optimized content: one FAQ-format article on a topic in your area, with sourced statistics and direct-answer structure. Submit the sitemap to the major search and AI-indexing tools.
• Launch the quarterly investor update: a substantive four to six paragraph note to opted-in contacts, framed as a scientific progress reflection with one milestone, one transparency moment, one upcoming catalyst, and one request for introductions or feedback.
• Run the first webinar if resources allow. A founder scientific-thesis webinar positions you as the most credible voice on your disease area and produces replay content that compounds for months.

Q4: Conversion (Months 10 to 12)

The fourth quarter turns twelve months of credibility infrastructure into warmer, more efficient conversations.

• Use accumulated visibility as context in formal investor outreach, the stage where most founders lose momentum if they have not diagnosed why outreach typically fails at earlier stages. Reference specific published articles and conference appearances in pitch emails built to actually get replies. An investor who has already encountered your content arrives at the first meeting with familiarity no cold email alone creates.
• Deploy ABM tactics to named partner targets: share specific content relevant to each target’s stated therapeutic interests, through LinkedIn, email, or conference follow-up. Referencing a specific piece of published work is far more credible than a generic partnership inquiry.
• Measure marketing’s contribution to warm pipeline. Calculate what proportion of investor meetings this quarter were preceded by content engagement, and which channels produced the highest-quality introductions. Use that data to reallocate Year 2 effort toward what worked.
• Plan the Year 2 content calendar backward from anticipated scientific, regulatory, and clinical milestones, so the content you publish in the months before each event creates the familiarity that makes the announcement land on a pre-warmed audience.

Why This Work Is Hard to Resource

Now the resourcing question, which is where most founders undo everything above. The reason it is genuinely difficult is that the job requires an unusual combination.

The Skill Set Is Rare

You need someone who can hold three things at once. Scientific literacy sufficient to translate the work without distorting it. Commercial judgment about capital, partnerships, and positioning. Compliance instinct for a regulated, IP-sensitive environment. Marketers with all three are uncommon. Marketers with all three who will join a pre-revenue company are rarer still.

The Full-Time Math Does Not Work Early

The economics are stark. Commonly cited market ranges put full-time CMO compensation at growth stage at roughly 225,000 to 600,000 dollars once base, bonus, and equity are counted, with executive search firms charging 20 to 25 percent of first-year compensation as a placement fee.

For a company whose entire seed round might be two million dollars, that is not a hiring decision. It is a strategic bet you cannot afford.

There is also a capacity problem that cuts the other way. Most seed and Series A biotechs do not have forty hours a week of executive-level marketing work. They have ten to fifteen hours of senior judgment, plus execution that someone more junior should be doing.

The Equity Cost Nobody Mentions

Here is the part left out of the standard comparison. Early-stage marketing-leader equity grants commonly fall between 0.5 and 2 percent of the company, and that is real dilution at exactly the stage when your equity is most expensive. In software that might be acceptable.

In biotech, where you will raise more rounds over more years and dilution compounds the entire way, giving up one or two points for a hire you may not need full-time is a decision worth examining hard against the broader question of how much equity biotech founders should give up at each stage. Early equity is the most expensive equity you will ever sell.

The Four Ways to Resource It

Founder-led, agency, in-house, or fractional. Each is right in specific circumstances and wrong in others.

Founder-Led

Right when you are pre-seed, the story is still forming, and your own credibility is the asset. This is the reality behind pre-seed fundraising with no clinical data yet to point to: founder-led stays correct for longer in biotech than in most sectors, because the founder’s scientific authority is precisely what the audience wants. Wrong when it stops scaling, which shows up as inconsistency, a stalled presence, or a founder too stretched across fundraising and R&D to sustain it.

Agency

Right when you have a clear strategy and need execution capacity to deliver it. Wrong when you have no strategy, which is the classic and expensive failure. Founders routinely burn substantial budget with an agency before realizing the problem was never execution but the absence of anyone setting direction, and that once a senior leader steers the work, the same agency starts producing results. Agencies execute. They do not decide.

In-House Hire

Right when you have consistent, full-time leadership needs and the budget to support them, typically at Series B and beyond or approaching commercial launch. Wrong when you are early, cash-constrained, and cannot yet define the role well enough to hire against it. A premature senior hire is expensive to make and painful to unwind.

Fractional

Right when you need senior strategic ownership but have neither the budget nor the volume of work for a full-time executive. A fractional leader is a senior operator working part-time, typically ten to twenty hours a week, who owns the strategy and directs execution rather than performing it.

This is not a consultant who advises and leaves, and it is not a freelancer executing tasks. Commonly cited retainers run 8,000 to 15,000 dollars a month for experienced operators at seed to Series A, with no equity grant and no search fee.

The model is now mainstream rather than a fallback. Gartner has forecast that by 2027 more than 30 percent of midsize enterprises will have at least one fractional executive on retainer, and within life sciences specifically, a meaningful share of biopharma professionals now report having worked in a fractional role.

The Hybrid That Usually Wins

For most seed to Series A life-science companies, the answer is not one of the four. It is fractional leadership setting strategy and owning outcomes, with an agency, contractors, or a junior in-house marketer executing underneath it. You buy senior judgment, which is what you lack, and you buy execution capacity separately, which is cheaper.

This is the structure that fits the actual shape of the work: a lot of execution, a little senior direction, and no room for a 400,000-dollar hire to do either.

When Fractional Is the Wrong Call

An honest guide has to include this, because the model is oversold. Do not hire a fractional marketing leader if any of the following is true.

• You are pre-seed with no clear story yet. Your job is to sharpen the science and the thesis. Founder-led visibility is enough, and a fractional leader will be strategizing in a vacuum.
• You need hands on keyboard. If what you actually need is someone to write, design, and publish, hire an execution resource. A fractional leader doing the work themselves is an expensive freelancer.
• You will not give them ownership. The model depends on real decision authority. If you plan to overrule every call, you are paying senior rates for advice you will ignore.
• You cannot commit six months. Credibility work compounds. Three months produces a strategy document and no results.
• You genuinely need a full-time leader. If you have forty hours a week of executive marketing work and a team to manage, hire the CMO. Fractional is not a discount version of that.

The test is simple. Fractional is right when your problem is a lack of senior direction. It is wrong when your problem is a lack of hands.

Matching the Model to Your Stage

The right model shifts as the company moves through each of the biotech funding stages, because what investors expect from your visibility changes at every round.

Pre-seed. Founder-led. Sharpen the story, build the founder’s public credibility, spend nothing on infrastructure.

Seed. Founder-led plus targeted support, or a light fractional engagement if fundraising is the bottleneck and the founder is out of capacity.

Series A. The fractional sweet spot. The company needs real positioning, investor visibility, and a business-development pipeline, but cannot justify a full-time executive. This is also where the bar for a Series A raise rises sharply on valuation and process, which is exactly why the marketing infrastructure needs to already be running.

Series B and toward commercialization. The calculus shifts. Volume of work rises, a team needs managing, and a full-time hire starts to make sense. A good fractional leader will tell you when you have reached this point, and often helps you hire your successor.

What a Competent First Quarter Looks Like

Whatever model you choose, a competent engagement produces, in its first quarter, a clear positioning of the science for investor and partner audiences, a defined target list, an agreed set of the metrics above, and a running system for visibility rather than a document about one. If ninety days produces a strategy deck and nothing operating, that is a red flag, and it is the same red flag whether the person producing it is a fractional leader, an agency, or a new full-time hire.

Growth Means Capital, Partnerships, Talent, and Credibility

Growth marketing for a pre-revenue biotech is not a smaller version of software growth marketing. It is a different discipline with a different objective.

Growth means capital, partnerships, talent, and credibility, not customers and acquisition cost, because the value of a biotech is built almost entirely before it has a product to sell.

The currency is trust in the science, so the work is credibility generation, not demand generation, and promotional marketing actively backfires with this audience.

The system is coherent because all four audiences read the same signals, which is why one layered narrative, five credibility-first channels, and metrics wired into the pipeline outperform four disconnected campaigns.

The job is hard to resource, because it needs scientific literacy, commercial judgment, and compliance instinct at once, and the full-time math rarely works early once you count the equity. Fractional leadership fits the gap when your problem is a lack of senior direction, and it is the wrong answer when your problem is a lack of hands.

Get the definition of growth right and the rest mostly answers itself. Get it wrong, and you will spend money measuring the wrong things while the audience that actually decides your future, the investors, partners, and scientists who could fund, accelerate, and join you, never hears your name.

---

If you are interested in working together to build a growth marketing system that builds the credibility your investors and partners are actually looking for, book a strategy call and let’s start building yours.

---

Frequently Asked Questions

---